公开(公告)号：US11472879B2

公开(公告)日：2022-10-18

申请号：US16778523

申请日：2020-01-31

Applicant: UCB Biopharma SRL

Inventor： Helene Margaret Finney ,  Stephen Edward Rapecki ,  Kerry Louise Tyson ,  Michael John Wright

IPC: C07K16/28 ,  A01K67/027 ,  A61K39/00

Abstract: The present disclosure relates to antibody molecules comprising a binding domain specific to CD22, said binding domain comprising SEQ ID NO: 1, 2, 3, 4, 5 and 6 or 7. The disclosure also extends to pharmaceutical compositions comprising said antibody molecules and use of the antibody molecules/compositions in treatment.

公开(公告)号：US20230074381A1

公开(公告)日：2023-03-09

申请号：US17804934

申请日：2022-06-01

Applicant: UCB Biopharma SRL

Inventor： Helene Margaret Finney ,  Alastair David Griffiths Lawson ,  Stevan Graham Shaw ,  Bryan John Smith ,  Kerry Louise Tyson ,  Lara Kevorkian ,  Christoph Meier ,  Kaushik Sarkar ,  Paul Alan Atherfold

IPC: C07K16/28 ,  G01N33/50 ,  G01N33/564 ,  G01N33/68 ,  A61K47/60 ,  A61K47/64 ,  A61K39/395

Abstract: The disclosure relates to antibodies specific to FcRn, formulations comprising the same, use of each in therapy, processes for expressing and optionally formulating said antibody, DNA encoding the antibodies and hosts comprising said DNA.

公开(公告)号：US10954312B2

公开(公告)日：2021-03-23

申请号：US15779428

申请日：2016-12-01

Applicant: UCB BIOPHARMA SRL

Inventor： Helene Margaret Finney

IPC: G01N33/53 ,  G01N33/68 ,  C07K16/00 ,  C07K16/30 ,  C07K16/46 ,  C07K14/39 ,  A61P35/00 ,  C07K16/14 ,  A61K39/00

Abstract: The present invention is directed to a method of controlling and directing cells, for example to stimulate an immune response, inhibit an immune response, direct tissue regeneration or prevent tissue damage for therapeutic activity through the use of heterodimerically-tethered bispecific protein complex of formula A-X:Y-B. Component A may present X on the surface of a cell, may bind a protein (including a marker) expressed on the surface of an effector cell, or A-X is expressed on the surface of an effector cell, whilst B is specific to an epitope on target cell or tissue of interest. X:Y is a heterodimeric-tether which is formed by a binding interaction between X and Y, which together with A and B assists and effects the controlling and directing of the selected cells.

公开(公告)号：US11261252B2

公开(公告)日：2022-03-01

申请号：US16513002

申请日：2019-07-16

Applicant: UCB BIOPHARMA SRL

Inventor： Helene Margaret Finney ,  Stephen Edward Rapecki ,  Michael John Wright ,  Kerry Louise Tyson

IPC: C07K16/28 ,  C07K16/18 ,  A61K39/00

Abstract: The present disclosure relates to multispecific molecule comprising a binding domain specific to the antigen CD22 and a binding domain specific to the antigen CD79a and/or CD79b, compositions comprising the same and use of both in treatment, for example the treatment of autoimmune disease.